{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T17:29:55Z","timestamp":1750094995807},"reference-count":71,"publisher":"Informa UK Limited","issue":"8","funder":[{"name":"is not funded"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Biological Therapy"],"published-print":{"date-parts":[[2021,8,3]]},"DOI":"10.1080\/14712598.2021.1889509","type":"journal-article","created":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T01:28:51Z","timestamp":1613352531000},"page":"1013-1023","update-policy":"http:\/\/dx.doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":7,"title":["Rituximab in Myasthenia Gravis - Where do we stand?"],"prefix":"10.1080","volume":"21","author":[{"given":"Zaeem A.","family":"Siddiqi","sequence":"first","affiliation":[{"name":"Division of Neurology, Dept of Medicine, University of Alberta Hospital, Edmonton, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wasim","family":"Khan","sequence":"additional","affiliation":[{"name":"Division of Neurology, Dept of Medicine, University of Alberta Hospital, Edmonton, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faraz S.","family":"Hussain","sequence":"additional","affiliation":[{"name":"Division of Neurology, Dept of Medicine, University of Alberta Hospital, Edmonton, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2021,4,2]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-015-0398-y"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2377-10-46"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2013.03.001"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1586\/eci.12.34"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2013.12.004"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1602678"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1111\/ene.12359"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2019.06.002"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26156"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1177\/1756285611411503"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26318"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197603252941303"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.311"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000647"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26919"},{"key":"cit0016","unstructured":"Soliris 300 product information. [cited 2020 Jun 23]. Available from: https:\/\/www.ema.europa.eu\/documents\/product-information\/soliris-epar-product-information_en.pdf."},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30369-1"},{"issue":"1","key":"cit0018","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/mus.26447","volume":"60","author":"Muppidi S","year":"2019","journal-title":"Muscle Nerve"},{"key":"cit0019","unstructured":"Alexion Pharmaceuticals, Inc. Eculizumab for use in AChR+ gMG. [cited 2020 Jun 23]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/125166s422lbl.pdf."},{"key":"cit0020","unstructured":"[cited 2020 Dec 18]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/orphan-designation\/eu\/3\/14\/1304-public-summary-opinion-orphan-designation-eculizumab-treatment-myasthenia-gravis_en.pdf"},{"key":"cit0021","volume":"12","author":"Sheridan D","year":"2018","journal-title":"PLoS One"},{"key":"cit0022","unstructured":"Safety and efficacy study of Ravulizumab in adults with generalized myasthenia gravis. Accessed 2020 Aug 2. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03920293."},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.939.939"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2019.5125"},{"key":"cit0025","unstructured":"Zilucoplan FDA Approval. Accessed 2020 Jun 23. https:\/\/www.accessdata.fda.gov\/scripts\/opdlisting\/oopd\/detailedIndex.cfm?cfgridkey=699"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1172\/JCI97911"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007600"},{"key":"cit0028","unstructured":"Argenx announces positive topline phase 3 ADAPT trial results. [cited 2020 Aug 2]. Available from: https:\/\/www.argenx.com\/news\/argenx-announces-positive-topline-phase-3-adapt-trial-results."},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan1208"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007600"},{"key":"cit0031","unstructured":"A study to test efficacy and safety of Rozanolixizumab in adult patients with generalized myasthenia gravis. [cited 2020 Dec 18]. Available from:\u00a0https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03971422."},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1276"},{"key":"cit0033","unstructured":"[cited 2020 Dec 18]. Available from: https:\/\/www.globenewswire.com\/news-release\/2020\/06\/15\/2047945\/0\/en\/Momenta-Pharmaceuticals-Announces-Positive-Topline-Data-from-Interim-Analysis-of-Phase-2-Vivacity-MG-Study-of-Nipocalimab-M281-in-Generalized-Myasthenia-Gravis-gMG.html."},{"key":"cit0034","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.92.15_supplement.P5.2-079","volume-title":"RVT-1401, A novel anti-FcRn monoclonal antibody, is well tolerated in healthy subjects and reduces plasma IgG following subcutaneous or intravenous administration","author":"Collins J","year":"2019"},{"key":"cit0035","unstructured":"Immunovant. Sciences GmbH. A study of RVT-1401 in myasthenia gravis (MG) patients. [cited 2020 Dec 20]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03863080?term=Immunovant&rank=3"},{"key":"cit0036","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000005323"},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.13377"},{"key":"cit0038","unstructured":"[cited 2020 Dec 20]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT02565576"},{"key":"cit0039","unstructured":"[cited 2020 Dec 20]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04524273"},{"key":"cit0040","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2006.01288.x"},{"key":"cit0041","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.990140212"},{"key":"cit0042","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.13562"},{"key":"cit0043","unstructured":"BeatMG: Phase II Trial of Rituximab In Myasthenia Gravis - Full Text View - ClinicalTrials.gov. [cited 2020 Jun 23]. Available from:\u00a0https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02110706"},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004341"},{"key":"cit0045","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182407982"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.1002\/mus.23412"},{"key":"cit0047","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2016.4190"},{"key":"cit0048","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2020.0851"},{"key":"cit0049","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25597"},{"key":"cit0050","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30078-9"},{"key":"cit0051","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-018-0295-0"},{"key":"cit0052","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2006.09.004"},{"key":"cit0053","doi-asserted-by":"publisher","DOI":"10.1177\/0091270005277075"},{"key":"cit0054","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.55.7.1062-a"},{"key":"cit0055","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2016.12.004"},{"key":"cit0056","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.564"},{"key":"cit0057","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbj.2017.02.002"},{"key":"cit0058","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2017.02.009"},{"key":"cit0059","doi-asserted-by":"publisher","DOI":"10.3205\/000239"},{"key":"cit0060","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-019-09191-6"},{"key":"cit0061","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.314"},{"key":"cit0062","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2017.05.021"},{"key":"cit0063","doi-asserted-by":"publisher","DOI":"10.3233\/JND-180300"},{"key":"cit0064","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14391"},{"key":"cit0065","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-014-7532-3"},{"key":"cit0066","unstructured":"A study evaluating the safety and efficacy of rituximab in patients with myasthenia gravis. Accessed 2020 Jun 24. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02950155"},{"key":"cit0067","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0000000000000202"},{"key":"cit0068","unstructured":"Rituximab FDA information. [cited 2020 Jun 25]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/103705s5367s5388lbl.pdf"},{"key":"cit0069","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/3762864"},{"volume-title":"Rituximab for the Treatment of Myasthenia Gravis: a Review of Clinical Effectiveness","year":"2019","author":"Banerjee S","key":"cit0070"},{"issue":"35","key":"cit0071","volume":"15","author":"Meriggioli MN","year":"2009","journal-title":"Continuum"}],"container-title":["Expert Opinion on Biological Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14712598.2021.1889509","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T06:33:35Z","timestamp":1724481215000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14712598.2021.1889509"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,2]]},"references-count":71,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8,3]]}},"alternative-id":["10.1080\/14712598.2021.1889509"],"URL":"https:\/\/doi.org\/10.1080\/14712598.2021.1889509","relation":{},"ISSN":["1471-2598","1744-7682"],"issn-type":[{"type":"print","value":"1471-2598"},{"type":"electronic","value":"1744-7682"}],"subject":[],"published":{"date-parts":[[2021,4,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-09-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}